Why Did SoFi Stock Drop?
Fintech platform SoFi (NASDAQ:SOFI) has stumbled in recent days, selling…
Sell
31
ABCL Quote, Financials, Valuation and Earnings
Last price:
$3.56
Seasonality move
:
-22.66%
Day range:
$3.53 - $3.69
52-week range:
$1.89 - $6.52
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
30.00x
P/B ratio:
1.11x
Volume:
2.3M
Avg. volume:
4.7M
1-year change:
24.91%
Market cap:
$1.1B
Revenue:
$28.8M
EPS (TTM):
-$0.58
Analysts' Opinion
-
Consensus RatingAbCellera Biologics, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 6 Buy ratings, 1 Hold rating, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $9.83, AbCellera Biologics, Inc. has an estimated upside of 176.22% from its current price of $3.56.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $7.00 representing 100% downside risk from its current price of $3.56.
Fair Value
-
According to the consensus of 7 analysts, AbCellera Biologics, Inc. has 176.22% upside to fair value with a price target of $9.83 per share.
ABCL vs. S&P 500
-
Over the past 5 trading days, AbCellera Biologics, Inc. has underperformed the S&P 500 by -4.85% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
AbCellera Biologics, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
AbCellera Biologics, Inc. has grown year-over-year revenues for 2 quarters straight. In the most recent quarter AbCellera Biologics, Inc. reported revenues of $9M.
Earnings Growth
-
AbCellera Biologics, Inc. earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter AbCellera Biologics, Inc. reported earnings per share of -$0.19.
Enterprise value:
687.2M
EV / Invested capital:
0.62x
Price / LTM sales:
30.00x
EV / EBIT:
--
EV / Revenue:
19.45x
PEG ratio (5yr expected):
-1.12x
EV / Free cash flow:
-4.52x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$522K
Return On Assets:
-12.52%
Net Income Margin (TTM):
-486.01%
Return On Equity:
-16.74%
Return On Invested Capital:
-15.28%
Operating Margin:
-851.79%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $50.4M | $33M | $35.3M | $6.5M | $9M | |
| Gross Profit | $2M | -$59.2M | $522K | -$31.8M | $1.7M | |
| Operating Income | -$207.4M | -$308.1M | -$261.3M | -$93.7M | -$76.3M | |
| EBITDA | -$170.2M | -$215.9M | -$226.5M | -$55.4M | -$69M | |
| Diluted EPS | -$0.45 | -$0.60 | -$0.58 | -$0.17 | -$0.19 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $803.7M | $1B | $919.5M | $742.9M | $695.1M | |
| Total Assets | $1.2B | $1.6B | $1.5B | $1.4B | $1.4B | |
| Current Liabilities | $49.5M | $106.1M | $110.2M | $79.6M | $68.8M | |
| Total Liabilities | $219.3M | $302.2M | $329.4M | $172.7M | $222.8M | |
| Total Equity | $953.4M | $1.3B | $1.2B | $1.1B | $964M | |
| Total Debt | $30.1M | $71.6M | $75.2M | $66.3M | $137.1M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$483.2K | -$119.3M | -$104.2M | -$29M | -$53.3M | |
| Cash From Investing | -$206.1M | $63.9M | $46.4M | $3.9M | $37.1M | |
| Cash From Financing | $7M | $12.2M | $14M | $3.2M | $7.5M | |
| Free Cash Flow | -$74.2M | -$195.3M | -$151.9M | -$47.6M | -$62.3M | |
ABCL
Sector
Market Cap
$1.1B
$28.5M
Price % of 52-Week High
54.64%
51.44%
Dividend Yield
0%
0%
Shareholder Yield
-0.83%
-1.33%
1-Year Price Total Return
24.91%
-20.32%
Beta (5-Year)
--
0.520
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$3.58
200-day SMA
Sell
Level
$3.65
Bollinger Bands (100)
Sell
Level
3.89 - 5.37
Chaikin Money Flow
Sell
Level
-25.3M
20-day SMA
Sell
Level
$3.66
Relative Strength Index (RSI14)
Sell
Level
36.95
ADX Line
Sell
Level
32.86
Williams %R
Neutral
Level
-54
50-day SMA
Sell
Level
$4.79
MACD (12, 26)
Sell
Level
-0.34
25-day Aroon Oscillator
Sell
Level
-60
On Balance Volume
Neutral
Level
692.5K
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (3.3368)
Buy
CA Score
(Annual)
Level (-0.1905)
Buy
Beneish M-Score
(Annual)
Level (-3.2699)
Buy
Momentum Score
Level (9)
Buy
Ohlson Score
Level (-1.0516)
Buy
Piotroski F Score
(Annual)
Level (4)
Sell
Quality Ratio Score
Level (3)
Buy
Fundamental Score
Level (4)
Revenue Forecast
Earnings per Share Forecast
Company Profile
AbCellera Biologics, Inc. engages in the development of therapeutic antibodies. It offers antibody discovery platform that searches, decodes and analyzes natural immune systems to find antibodies that can be developed to prevent and treat disease. The company was founded by Carl Lars G. Hensen, Kathleen Lisaingo, Kevin Heyries, Véronique Lecault and Daniel Da Costa on November 8, 2012 and is headquartered in Vancouver, Canada.
Stock Forecast FAQ
In the current month, ABCL has received 6 Buy ratings 1 Hold ratings, and 0 Sell ratings. The ABCL average analyst price target in the past 3 months is $9.83.
-
Where Will AbCellera Biologics, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that AbCellera Biologics, Inc. share price will rise to $9.83 per share over the next 12 months.
-
What Do Analysts Say About AbCellera Biologics, Inc.?
Analysts are divided on their view about AbCellera Biologics, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that AbCellera Biologics, Inc. is a Sell and believe this share price will drop from its current level to $7.00.
-
What Is AbCellera Biologics, Inc.'s Price Target?
The price target for AbCellera Biologics, Inc. over the next 1-year time period is forecast to be $9.83 according to 7 Wall Street analysts, 6 of them rate the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is ABCL A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for AbCellera Biologics, Inc. is a Buy. 6 of 7 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of ABCL?
You can purchase shares of AbCellera Biologics, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase AbCellera Biologics, Inc. shares.
-
What Is The AbCellera Biologics, Inc. Share Price Today?
AbCellera Biologics, Inc. was last trading at $3.56 per share. This represents the most recent stock quote for AbCellera Biologics, Inc.. Yesterday, AbCellera Biologics, Inc. closed at $3.56 per share.
-
How To Buy AbCellera Biologics, Inc. Stock Online?
In order to purchase AbCellera Biologics, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get ABCL Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
ABCL
Sector
P/E ratio
--
23.75x
PEG ratio
-1.12x
-0.01x
P/B ratio
1.11x
1.83x
Price / LTM sales
30.00x
1.60x
Growth Metrics
ABCL
Sector
Revenue growth
37.62%
4.85%
Earnings growth
-10.27%
11.11%
Revenue (5-year growth)
19.95%
6.45%
Earnings forecast
-$0.16
-$0.20
Profitability
ABCL
Sector
Profitability FY 2024
-$68.2M
$3.6M
Return on invested capital
-15.28%
-30.98%
Return on assets
-12.52%
-27.62%
Return on equity
-16.74%
-36.69%
Earnings Date
Last Earnings Date
Nov
6
Next Earnings Date
Feb
26
Estimated Next Earnings Date
Feb
5
Balance Sheet
ABCL
Sector
Total cash
$520.7M
$27.2M
Short term investments
$469.3M
$25.7M
Total assets
$1.4B
$79.7M
Long term debt
$137.1M
$4.1M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Robinhood Win AI Investing?
Recently, online brokerage Robinhood (NASDAQ:HOOD) has been focused on introducing…
Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Buy
56
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
81
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 40x
Alerts
Buy
56
SMX alert for Dec 6
SMX (Security Matters) Plc [SMX] is up 134.09% over the past day.
Buy
62
PRAX alert for Dec 6
Praxis Precision Medicines, Inc. [PRAX] is up 30.47% over the past day.
Sell
13
PSN alert for Dec 6
Parsons Corp. [PSN] is down 21.1% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
